Peptides, demystified: signaling molecules in plain English.

A peptide is a short chain of amino acids — the same building blocks as proteins, just fewer of them. Your body makes thousands and uses them as signals: instructions passed between cells to start, stop or modify a process.

Therapeutic peptides borrow that language. Rather than blocking a receptor or killing a pathogen, they tend to nudge a system your body already runs. That is the appeal, and it is also why the category attracts more enthusiasm than its evidence sometimes warrants.

Here is where the commonly discussed ones actually stand.

GLP-1 receptor agonists

These are the best evidenced by a wide margin, and the only group here with large approved indications behind them.

GLP-1 is a hormone released by the gut after eating. It prompts insulin release when glucose is elevated, suppresses glucagon, slows gastric emptying and signals satiety centrally. The medications in this class — semaglutide and tirzepatide among them, the latter acting at both GIP and GLP-1 receptors — extend that signal.

They are FDA-approved for type 2 diabetes and, at specific doses and under specific brand names, for weight management. Cardiovascular outcome data supports benefit in defined populations.

The honest counterweight: gastrointestinal side effects are common, they are generally ongoing medications rather than a course, meaningful loss of lean mass can accompany weight reduction if resistance training and protein intake are neglected, and there are contraindications that must be taken seriously — including personal or family history of medullary thyroid carcinoma or MEN2. Compounded versions raise separate concerns about content and consistency. These are real medications with real considerations, and they belong under supervision.

Growth hormone secretagogues: CJC-1295, ipamorelin, sermorelin, tesamorelin

Rather than administering growth hormone, these prompt the pituitary to release its own — in something closer to its natural pulsatile pattern, which is the theoretical advantage.

Regulatory status varies considerably within this group and is worth separating. Tesamorelin is FDA-approved for a specific indication. Sermorelin has a longer clinical history. Others, including CJC-1295 and ipamorelin, do not have FDA approval for general use, and several peptides in this space have been placed by the FDA into a category identifying substantial safety concerns for compounding.

Human evidence for the anti-ageing and body-composition claims made commercially is thinner than the marketing implies. Stimulating the GH/IGF-1 axis is also not a neutral act — that axis interacts with growth signalling generally, which is a reason for caution rather than alarm, and a reason to monitor IGF-1 rather than dose blindly.

"Natural" and "your own hormone" are not the same as "without consequence." Anything strong enough to change how you feel is strong enough to warrant monitoring.

BPC-157

Probably the most discussed peptide in fitness and recovery circles, and the one where the gap between reputation and evidence is widest.

It is a synthetic fragment related to a protein found in gastric juice, and it has been studied largely in animals — where results in tendon, muscle and gut healing have been genuinely striking.

The problem is what follows. Published human clinical trial data is minimal. It is not FDA-approved, it appears on the FDA's list of substances raising significant safety concerns for compounding, and it is prohibited by the World Anti-Doping Agency, which matters for anyone competing.

I will not tell you the animal work is uninteresting, because it is not. I will tell you that "extensively studied in rodents" and "established in humans" are separated by a distance that marketing routinely collapses, and that anyone offering it should be saying so.

GHK-Cu

A copper-binding peptide found naturally in plasma, with declining levels across adult life. Its best-supported use is topical, in skin — where there is reasonable evidence for effects on collagen and the appearance of ageing skin, and where it appears in cosmetic formulations.

Claims extending to systemic injectable use for wound healing or hair growth rest on far less human data. As a skincare ingredient it is well founded. As an injectable for broad indications it is not.

How we decide

Four questions, in order.

What is the actual goal, and is a peptide the right tool for it? Poor recovery caused by five hours of sleep and low ferritin is not a peptide problem. A great deal of what peptides are asked to fix is better addressed upstream, and doing that first also makes it possible to tell whether the peptide did anything.

What does the evidence support for this person? Not for the category. For this indication, in humans.

What is the regulatory and sourcing position? Approved product, compounded from a licensed pharmacy, or research chemical from the internet — these are entirely different risk profiles, and the last one is not something a clinic should be facilitating.

What are we measuring, and when do we stop? Baseline labs, a defined review point, and an honest answer if nothing has changed. A protocol without an exit criterion is a subscription, not a treatment.

Used that way, peptides are a useful part of a plan. Sold as a catalogue, they are mostly an expensive way to feel like something is being done.

This article is educational and is not medical advice, diagnosis, or treatment. Laboratory results and therapies require interpretation in the context of your history, symptoms, medications, and examination, and what is appropriate differs from person to person. Nothing here should be used to start, stop, or change any treatment. Please speak with a qualified clinician who knows your case.